In the latest session, Medtronic plc (NYSE: MDT) closed at $83.54 down -4.51% from its previous closing price of $87.49. In other words, the price has decreased by -$3.95 from its previous closing price. On the day, 12170254 shares were traded. MDT stock price reached its highest trading level at $85.40 during the session, while it also had its lowest trading level at $82.31.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
For a deeper understanding of Medtronic plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 180.68. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.43.
Upgrades & Downgrades
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 30 when Medtronic plc bought 6,835 shares for $9.28 per share. The transaction valued at 63,436 led to the insider holds 4,999,423 shares of the business.
Salmon Sean sold 16,631 shares of MDT for $1,338,736 on Dec 13. The EVP & President Cardiovascular now owns 36,088 shares after completing the transaction at $80.50 per share. On Oct 14, another insider, TEN HOEDT ROB, who serves as the EVP and Pres. Global Regions of the company, sold 2,404 shares for $81.54 each. As a result, the insider received 196,015 and left with 43,483 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDT now has a Market Capitalization of 119.82B and an Enterprise Value of 136.81B. As of this moment, Medtronic’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.46, and their Forward P/E ratio for the next fiscal year is 16.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 26.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.60 while its Price-to-Book (P/B) ratio in mrq is 2.16. Its current Enterprise Value per Revenue stands at 4.45 whereas that against EBITDA is 15.70.
Stock Price History:
Over the past 52 weeks, MDT has reached a high of $106.06, while it has fallen to a 52-week low of $75.76. The 50-Day Moving Average of the stock is 84.75, while the 200-Day Moving Average is calculated to be 83.70.
For the past three months, MDT has traded an average of 5.89M shares per day and 5.95M over the past ten days. A total of 1.33B shares are outstanding, with a floating share count of 1.33B. Insiders hold about 0.09% of the company’s shares, while institutions hold 84.60% stake in the company. Shares short for MDT as of Apr 27, 2023 were 11.41M with a Short Ratio of 10.70M, compared to 7.75M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 0.86% and a Short% of Float of 0.86%.
Dividends & Splits
According to the company, the forward annual dividend rate for MDT is 2.72, from 2.67 in the trailing year. Against a Trailing Annual Dividend Yield of 3.05%, it implies a Forward Annual Dividend Yield of 3.04%. The stock’s 5-year Average Dividend Yield is 2.28. The current Payout Ratio is 87.50% for MDT, which recently paid a dividend on Apr 13, 2023 with an ex-dividend date of Mar 22, 2023. Stock splits for the company last occurred on Sep 26, 1999 when the company split stock in a 2:1 ratio.
There are 25 different market analysts currently analyzing its stock. On average, analysts expect EPS of $1.56 for the current quarter, with a high estimate of $1.57 and a low estimate of $1.54, while EPS last year was $1.52. The consensus estimate for the next quarter is $1.14, with high estimates of $1.25 and low estimates of $1.07.
Analysts are recommending an EPS of between $5.31 and $5.26 for the fiscal current year, implying an average EPS of $5.28. EPS for the following year is $5.2, with 30 analysts recommending between $5.45 and $5.
A total of 22 analysts believe the company’s revenue will be $8.25B this quarter.It ranges from a high estimate of $8.38B to a low estimate of $8.2B. As of the current estimate, Medtronic plc’s year-ago sales were $8.09B, an estimated increase of 2.00% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $7.67B, an increase of 4.10% over than the figure of $2.00% in the same quarter last year. There is a high estimate of $7.88B for the next quarter, whereas the lowest estimate is $7.46B.
A total of 29 analysts have provided revenue estimates for MDT’s current fiscal year. The highest revenue estimate was $31.06B, while the lowest revenue estimate was $30.82B, resulting in an average revenue estimate of $30.93B. In the same quarter a year ago, actual revenue was $31.69B, down -2.40% from the average estimate. Based on 29 analysts’ estimates, the company’s revenue will be $32.28B in the next fiscal year. The high estimate is $32.6B and the low estimate is $31.84B. The average revenue growth estimate for next year is up 4.40% from the average revenue estimate for this year.